Vijayakrishna Gadi, MD, University of Illinois College of Medicine

Best practices for preventing and managing treatment-related adverse events associated with systemic therapies used to treat HER2-positive metastatic breast cancer.

Dr Lee Schwartzberg, MD, FASCO, highlights the appropriateness for treating HER2-positive metastatic breast cancer with either neratinib plus capecitabine or margetuximab plus chemotherapy based on evidence revealed by the NALA and SOPHIA clinical trials.

Considerations for initiating trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who received previous treatment with trastuzumab emtansine based on data demonstrated by the DESTINY-Breast01 study.

The significance of the HER2CLIMB study of tucatinib in combination with capecitabine and trastuzumab as treatment for patients with HER2-positive metastatic breast cancer.

Current treatment approaches available to treat HER2-positive metastatic breast cancer in the first- and second-line treatment settings.